146117-78-4

146117-78-4 structure

Name: LY191704
Chemical Name: (4aS,10bS)-8-chloro-4-methyl-1,2,4a,5,6,10b-hexahydrobenzo[f]quinolin-3-one
CAS Number: 146117-78-4
Molecular Formula: C₁₄H₁₆ClNO
Molecular Weight: 249.73600
Catalog: Signaling Pathways Metabolic Enzyme/Protease 5 alpha Reductase
Create Date: 2017-04-25 15:33:06
Modify Date: 2024-01-10 16:16:40
LY191704, as a benzoquinolinone, is a potent, nonsteroidal, noncompetitive and selective human type I 5α-reductase inhibitor. LY191704 is a racemic mixture of the compounds LY300502 and LY300503. LY191704 may be useful in the research of human endocrine disorders associated with overproduction of dihydrotestosterone (DHT) by 5α-reductase type 1[1][2].

Name	(4aS,10bS)-8-chloro-4-methyl-1,2,4a,5,6,10b-hexahydrobenzo[f]quinolin-3-one
Synonyms	8-Chloro-4-methyl-1,2,3,4,4a,5,6,10b-octahydrobenzo(f)quinolin-3(2H)-one Benzo(f)quinolin-3(2H)-one,8-chloro-1,4,4a,5,6,10b-hexahydro-4-methyl-,trans

Description	LY191704, as a benzoquinolinone, is a potent, nonsteroidal, noncompetitive and selective human type I 5α-reductase inhibitor. LY191704 is a racemic mixture of the compounds LY300502 and LY300503. LY191704 may be useful in the research of human endocrine disorders associated with overproduction of dihydrotestosterone (DHT) by 5α-reductase type 1[1][2].
Related Catalog	Research Areas >> Endocrinology Signaling Pathways >> Metabolic Enzyme/Protease >> 5 alpha Reductase
Target	Human Type I 5α-Reductase[1][2]
In Vitro	LY191704 (0.001-100 uM) inhibits the conversion of testosterone to DHT with an IC50 of 10 nM in Hs68 cells. LY191704 inhibits the enzyme expressed by the human cells with an IC50 of 12 nM but is virtually inactive against the 5α-reductase expressed by rat prostate cells. LY191704 is a potent and specific inhibitor of human 5α-reductase type 1 but had little or no activity against human 5α-reductase type 2 or rat 5α-reductase type 1. A Ki value of 17.1 μM is determined for the human type 2 enzyme, indicating that LY191704 demonstrates an 5000-fold selectivity for the human type 1 isozyme[2].
In Vivo	LY191704 (10, 30, or 100 mg/kg; p.o.; 1 month) increases plasma concentrations[1]. Animal Model: Rats[1] Dosage: 10, 30, or 100 mg/kg Administration: P.o.; 1 month Result: Increased plasma concentrations.
References	[1]. Farid NA, et al. Stereoselective disposition of the enantiomers of the benzoquinolinone LY191704, a human type I 5 alpha-reductase inhibitor. Differences between rats and dogs. Drug Metab Dispos. 1996;24(10):1162-1165. [2]. Hirsch KS, et al. LY191704: a selective, nonsteroidal inhibitor of human steroid 5 alpha-reductase type 1. Proc Natl Acad Sci U S A. 1993;90(11):5277-5281.

Molecular Formula	C₁₄H₁₆ClNO
Molecular Weight	249.73600
Exact Mass	249.09200
PSA	20.31000
LogP	2.92850
Vapour Pressure	4.65E-07mmHg at 25°C

56-41-7	108-65-6
56-35-9	64-17-5
67-56-1	108-88-3
141-78-6	1310-73-2
13463-67-7	1333-86-4